Nothing Special   »   [go: up one dir, main page]

FI935724A0 - (S) (+) - 2-ethoxy-4- / N- / 1- (2-piperidinofenyl) -3-methyl-1-butyl / aminokarbonylmetyl / -bensoesyra - Google Patents

(S) (+) - 2-ethoxy-4- / N- / 1- (2-piperidinofenyl) -3-methyl-1-butyl / aminokarbonylmetyl / -bensoesyra

Info

Publication number
FI935724A0
FI935724A0 FI935724A FI935724A FI935724A0 FI 935724 A0 FI935724 A0 FI 935724A0 FI 935724 A FI935724 A FI 935724A FI 935724 A FI935724 A FI 935724A FI 935724 A0 FI935724 A0 FI 935724A0
Authority
FI
Finland
Prior art keywords
piperidinofenyl
bensoesyra
aminokarbonylmetyl
ethoxy
butyl
Prior art date
Application number
FI935724A
Other languages
Finnish (fi)
Other versions
FI106027B (en
FI935724A (en
Inventor
Wolfgang Grell
Andreas Greischel
Gabriele Zahn
Michael Mark
Hansjoerg Knorr
Eckhard Rupprecht
Ulrich Mueller
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36781542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI935724(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of FI935724A publication Critical patent/FI935724A/en
Publication of FI935724A0 publication Critical patent/FI935724A0/en
Application granted granted Critical
Publication of FI106027B publication Critical patent/FI106027B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI935724A 1991-06-21 1993-12-20 A process for the preparation of (S) (+) - 2-ethoxy-4- [N- [1- (2-piperidinophenyl) -3-methyl-1-butyl] aminocarbonylmethyl] -benzoic acid or its salt, and (S) -1- ( Preparation of N-acetyl-L-glutamine salt of 2-piperidinophenyl) -3-methyl-1-butylamine FI106027B (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP9101147 1991-06-21
SG1996002715A SG43036A1 (en) 1991-06-21 1991-06-21 (S) (+) -2-ethoxy-4-[N-[1-(2-piperidino-phenyl)-3-methyl- 1-buthyl]aminocarbony methyl] - benzoic a cid
SG9602715 1991-06-21
PCT/EP1991/001147 WO1993000337A1 (en) 1991-06-21 1991-06-21 (s)(+)-2-ethoxy-4-[n-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid
CA002111851A CA2111851C (en) 1991-06-21 1991-06-21 (s)(+)-2-ethoxy-4-[n-{1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid
CA2111851 1991-06-21
CN91104984 1991-07-22
CN91104984A CN1048722C (en) 1991-06-21 1991-07-22 (S)(+)-2-Ethoxy-4-[N-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]-aminocarbonylmethyl]-benzoic acid, pharmaceutical compositions containing compound and processes for preparation thereof

Publications (3)

Publication Number Publication Date
FI935724A FI935724A (en) 1993-12-20
FI935724A0 true FI935724A0 (en) 1993-12-20
FI106027B FI106027B (en) 2000-11-15

Family

ID=36781542

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935724A FI106027B (en) 1991-06-21 1993-12-20 A process for the preparation of (S) (+) - 2-ethoxy-4- [N- [1- (2-piperidinophenyl) -3-methyl-1-butyl] aminocarbonylmethyl] -benzoic acid or its salt, and (S) -1- ( Preparation of N-acetyl-L-glutamine salt of 2-piperidinophenyl) -3-methyl-1-butylamine

Country Status (19)

Country Link
EP (1) EP0589874B1 (en)
JP (1) JP2921982B2 (en)
KR (1) KR100496720B1 (en)
CN (1) CN1048722C (en)
AU (1) AU660930B2 (en)
BG (1) BG61690B1 (en)
CA (1) CA2111851C (en)
DE (2) DE59109151D1 (en)
DK (2) DK0965591T3 (en)
FI (1) FI106027B (en)
GR (1) GR3031654T3 (en)
HK (1) HK1011968A1 (en)
NO (2) NO303687B1 (en)
PL (1) PL170210B1 (en)
RO (1) RO113462B1 (en)
SG (1) SG43036A1 (en)
SK (1) SK281246B6 (en)
UY (1) UY25923A1 (en)
WO (1) WO1993000337A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1097710B1 (en) 1997-06-13 2014-08-20 Novo Nordisk A/S Combination product for treating niddm
IN192862B (en) 1999-11-16 2004-05-22 Ranbaxy Lab Ltd
AR033390A1 (en) 2000-08-22 2003-12-17 Novartis Ag A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN ATTA RECEIVER ANTAGONIST AND A POTENTIATOR OF THE INSULIN SECRETION, THE USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A PARTS KIT
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US20040102477A1 (en) * 2002-08-23 2004-05-27 Dr. Reddy's Laboratories Limited Polymorphic forms of (S)-Repaglinide and the processes for preparation thereof
EP1636199A2 (en) * 2003-05-14 2006-03-22 Cilag AG Method for the production of phenylacetic acid derivatives
WO2004103983A1 (en) * 2003-05-26 2004-12-02 Biocon Limited Process for the preparation of s(+)-2-ethoxy-4-[n-{1-(2-piperidinophelyl)-3-methyl-1- butyl} aminocarbonylmethyl]benzoic acid derivatives
WO2005021524A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Process for the preparation of amorphous form of repaglinide
CN1305863C (en) * 2004-12-27 2007-03-21 浙江大学 Method for synthesizing (S)-isopropyl-(2-piperidine) phenyl-methylhistamine
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
FR2898894B1 (en) * 2006-03-24 2008-06-06 Genfit Sa SUBSTITUTED N- (PHENETHYL) BENZAMIDE DERIVATIVE COMPOUNDS, PREPARATION AND USES
US7763607B2 (en) * 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
MX2009004081A (en) * 2006-10-20 2009-06-18 Cpd Llc Method of restoring the incretin effect.
US8101769B2 (en) * 2007-02-15 2012-01-24 Actavis Group Ptc Ehf Process for preparing ethyl (S)-2-ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonyl methyl]benzoate and use thereof for the preparation of Repaglinide
US20100197732A1 (en) * 2007-06-06 2010-08-05 Actavis Group Ptc Ehf Repaglinide Substantially Free of Dimer Impurity
EP2019097A1 (en) 2007-07-25 2009-01-28 Aurobindo Pharma Limited Process for preparing (alphaS)-alpha-(2-methylpropyl)-2-(1-piperidinyl)benzenemethanamine
AU2008303129B2 (en) 2007-09-25 2013-08-01 Formulex Pharma Innovations Ltd. Compositions comprising lipophilic active compounds and method for their preparation
DE102008046995B4 (en) * 2008-09-12 2010-08-26 Stada Arzneimittel Ag 2-ethoxy-benzoic acid
EP2177221A1 (en) 2008-10-20 2010-04-21 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of substantially optically pure Repaglinide and precursors thereof
EP2430018B1 (en) 2009-05-15 2013-07-03 Novartis AG Benzoxazolone derivatives as aldosterone symthase inhibitors
EP2429995B1 (en) 2009-05-15 2014-01-22 Novartis AG Aryl pyridine as aldosterone synthase inhibitors
SG176010A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
UY32662A (en) 2009-05-28 2010-12-31 Novartis Ag AMINO-PROPIONIC DERIVATIVES REPLACED AS NEPRILISINE INHIBITORS
EP2501678B1 (en) 2009-11-17 2015-09-23 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
EP2364977A1 (en) 2010-01-26 2011-09-14 Reuter Chemische Apparatebau KG Process for the enantiomeric enrichment of 3-methyl-1-(2-piperidinophenyl)-1-butylamine
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CN102267959B (en) * 2011-07-06 2013-05-01 海南锦瑞制药股份有限公司 Repaglinide crystal, preparation method thereof, and solid oral preparation containing same
CN103012319B (en) * 2011-09-20 2015-06-10 浙江九洲药业股份有限公司 Repaglinide intermediate synthesis process improvement
CN102584743A (en) * 2011-12-28 2012-07-18 中国药科大学 Dimethylaminopyridine repaglinide eutectic
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
LT2956464T (en) 2013-02-14 2018-07-10 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
EA201690278A1 (en) 2013-07-25 2016-06-30 Новартис Аг CYCLIC POLYPEPTIDES FOR TREATMENT OF HEART FAILURE
MX2016001021A (en) 2013-07-25 2016-08-03 Novartis Ag Bioconjugates of synthetic apelin polypeptides.
ES2787223T3 (en) 2014-11-07 2020-10-15 Univ Minnesota Salts and compositions useful for treating diseases
CN107406490A (en) 2015-01-23 2017-11-28 诺华股份有限公司 Synthesis APELIN fatty acid conjugates with improved half-life period
WO2018034627A1 (en) 2016-08-18 2018-02-22 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Pharmaceutical composition of antidiabetic tablet
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347565A1 (en) * 1983-12-30 1985-07-11 Thomae Gmbh Dr K NEW PHENYL ACETIC DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
AU660930B2 (en) 1995-07-13
DK0965591T3 (en) 2002-11-18
PL170210B1 (en) 1996-11-29
FI106027B (en) 2000-11-15
HK1011968A1 (en) 1999-07-23
FI935724A (en) 1993-12-20
DK0589874T3 (en) 2000-04-03
CA2111851C (en) 2002-02-26
EP0589874A1 (en) 1994-04-06
NO303687B1 (en) 1998-08-17
NO934726D0 (en) 1993-12-20
SG43036A1 (en) 1997-10-17
KR100496720B1 (en) 2006-01-27
JP2921982B2 (en) 1999-07-19
CN1068820A (en) 1993-02-10
DE10075006I2 (en) 2004-01-08
DE10075006I1 (en) 2000-04-20
SK281246B6 (en) 2001-01-18
BG61690B1 (en) 1998-03-31
CN1048722C (en) 2000-01-26
JPH06508816A (en) 1994-10-06
RO113462B1 (en) 1998-07-30
NO934726L (en) 1993-12-20
GR3031654T3 (en) 2000-02-29
BG98300A (en) 1994-09-30
AU8078191A (en) 1993-01-25
CA2111851A1 (en) 1993-01-07
NO1999017I1 (en) 1999-07-20
WO1993000337A1 (en) 1993-01-07
SK128093A3 (en) 1994-11-09
UY25923A1 (en) 2001-08-27
EP0589874B1 (en) 1999-09-08
DE59109151D1 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
FI935724A (en) (S) (+) - 2-ethoxy-4- / N- / 1- (2-PIPERIDINOFENYL) -3-methyl-1-BUTYL / AMINOKARBONYLMETYL / -BENSOESYRA
FI925526A0 (en) CONTRAST MEASURES FOR ULTRALJUDSAVBILDNING
ATE137279T1 (en) HEADCASE
ATA131391A (en) REIBRING
DE4293023T1 (en) Quick connection recording
FI934710A (en) 4-Aryl-3- (HETEROARYLUREIDO) KINOLINDERIVAT
BR9202151A (en) REPLACED IMIDAZOLINYLPYRIMIDINES
ITTO920878A0 (en) VIOLIN
NO924464D0 (en) DATA DEKOERINGSANORDNING
ATA39792A (en) MAEHWERK
TR25953A (en) SUBSTITUTED 2-ARILPIROLES
ATE163916T1 (en) ETHYL-6-FORMYLOXY-4-HEXENOATE
ATA9892A (en) FORMSTEIN
ATA67791A (en) ROLLSKI
TR26694A (en) SUBSTITUTED 4-HETARIL-PIRAZOLINES
BR9205291A (en) PENTANOI REPLACED
ES1018290Y (en) TABLE-FRIDGE
KR930002463U (en) Case
ATA3092A (en) SCOPE
BR7101342U (en) HAMBURGUEIRA
BR7102423U (en) MIC-LAV
ATA23591A (en) MUENZKASSA
ATA235591A (en) ELUER
BR7100443U (en) VIGIER
BR7100567U (en) AUTO-TRANSPONDER

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: NOVO NORDISK A/S

Free format text: NOVO NORDISK A/S

MA Patent expired